Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2008

View Archived Issues

Antisoma to acquire Xanthus Pharma for GBP 26.8 million

Dynavax reports results from Tolamba chamber study

Inspire receives milestone payment of USD 1.25 million from Santen

RETRA active against mutant p53-bearing cancer cells

Zinc finger protein transcription factors show potential in treating pain

Ki-20227 reduces the severity of experimental autoimmune encephalomyelitis

Antidepressants reduce HIV infectivity of monocyte-derived macrophages

Paliperidone palmitate effective in phase III schizophrenia study

Blocking mast cell chymase decreases pulmonary response in ovine asthma model

Phenomix's PHX-1149 demonstrates positive phase II results

Prepandrix pre-pandemic influenza vaccine approved in Europe

Pharmaxis' Aridol receives marketing approval in Germany

KaloBios initiates phase I/II trial of KB-001 for Pseudomonas aeruginosa infections

Positive phase IIa results reported for AgaNase in nasal decolonization of S. aureus

Ark reports an update on EG-013 and EG-014 preclinical programs

Pharmasset selects PSI-7851 as lead development candidate for treatment of HCV

Mymetics acquires preventive malaria vaccine from Pevion Biotech

Ikaria completes dosing in phase Ia clinical study of IK-1001 for injection

FDA grants fast track designation to InterMune's development of pirfenidone for IPF

Pro-Pharmaceuticals enters collaboration with BioCancell to deliver siRNA intravenously

Tibotec Therapeutics launches new 600 mg tablet strength for Prezista in HIV

New antidiabetic agents disclosed in recent patents

Recent patents report new therapeutic agents for obesity and other metabolic disorders

Novel agents for anxiety, depression described in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...